The 7th International Partnering Forum “Life Sciences Invest. Partnering Russia” held in early November in St. Petersburg summed up the results of the past year and set the ways for further development of the industry.
Over the past 8 years, since the beginning of the active implementation of the “Pharma 2020” program, the right vector of development has been set and, today, the Russian pharmaceutical industry is the fastest growing sector in the country. In 2016, the Russian pharmaceutical companies were developing at a much more dynamic pace than their foreign counterparts. In that year, their revenues amounted to 314.5 billion rubles, that is 23.7% more than in 2015. At the same time, the volume of drugs imported to the Russian market increased by 8.1% over the year to reach 493.1 billion rubles.
“In a relatively short period of time, the sector made a strong industrial breakthrough based on innovation, advanced and effective R&D,” said the acting Governor of St. Petersburg Alexander Govorunov. “We see the opening of new plants, new modern production lines, and establishment of good foundations for future development.”
In 2016, the manufacturing of medicinal products in St. Petersburg increased by 40% compared to 2015 and reached more than 20 billion rubles. The revenues of BIOCAD amounted to 14.5 billion rubles; Geropharm, 4.7 billion rubles; Vertex, about 5 billion rubles; Polysan, 4 billion rubles. Moreover, for BIOCAD, the annual increase of revenues was 40%; for Geropharm, 35%; for Vertex, 25%; and for Polysan, 10%. In 2016, the pharmaceutical manufacturers of St. Petersburg exported their products to 26 countries for a total amount of more than 1.7 billion rubles. Today, there is every opportunity to ensure that St. Petersburg manufactures 10-12% of all medicinal products supplied to the Russian market.